Retatrutide, from Soma Corp., is attracting increasing attention as a innovative method for metabolic management . This innovative drug integrates the activity of a GLP-1 receptor agonist and a GIP receptor stimulant, aiming to not only promote weight loss but also target associated metabolic conditions . Early patient trials have shown promisin… Read More